Clinical impact of bone marrow morphology for the diagnosis of essential thrombocythemia: comparison between the BCSH and the WHO criteria.
作者信息
Gisslinger H, Jeryczynski G, Gisslinger B, Wölfler A, Burgstaller S, Buxhofer-Ausch V, Schalling M, Krauth M-T, Schiefer A-I, Kornauth C, Simonitsch-Klupp I, Beham-Schmid C, Müllauer L, Thiele J
出版信息
Leukemia. 2017 Mar;31(3):774-775. doi: 10.1038/leu.2016.291.
Abstract
摘要
相似文献
1
Clinical impact of bone marrow morphology for the diagnosis of essential thrombocythemia: comparison between the BCSH and the WHO criteria.
Leukemia. 2017 Mar;31(3):774-775. doi: 10.1038/leu.2016.291.
2
Clinical impact of bone marrow morphology for the diagnosis of essential thrombocythemia: comparison between the BCSH and the WHO criteria.
Leukemia. 2016 May;30(5):1126-32. doi: 10.1038/leu.2015.360. Epub 2015 Dec 29.
3
The 2014 BCSH criteria and the 2016 WHO criteria for essential thrombocythemia: A comparison in a large-scale cohort.
Eur J Haematol. 2018 Jun;100(6):544-549. doi: 10.1111/ejh.13041. Epub 2018 Apr 2.
4
Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
Pathol Biol (Paris). 2007 Mar;55(2):92-104. doi: 10.1016/j.patbio.2006.06.002. Epub 2006 Aug 21.
5
[Classification and diagnosis of essential thrombocythemia].
Rinsho Byori. 2012 Jun;60(6):553-9.
6
Relevance of bone marrow features in the differential diagnosis between essential thrombocythemia and early stage idiopathic myelofibrosis.
Haematologica. 2000 Nov;85(11):1126-34.
7
Proposal for revised diagnostic criteria of essential thrombocythemia and polycythemia vera by the Thrombocythemia Vera Study Group.
Semin Thromb Hemost. 1997;23(4):339-47. doi: 10.1055/s-2007-996107.
8
Masked polycythemia vera diagnosed according to WHO and BCSH classification.
Am J Hematol. 2014 Feb;89(2):199-202. doi: 10.1002/ajh.23617.
9
Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.
Arch Pathol Lab Med. 2014 Sep;138(9):1203-9. doi: 10.5858/arpa.2013-0018-OA.
10
Discriminating between essential thrombocythemia and masked polycythemia vera in JAK2 mutated patients.
Am J Hematol. 2014 Jun;89(6):588-90. doi: 10.1002/ajh.23694. Epub 2014 Mar 3.
引用本文的文献
1
High-accuracy morphological identification of bone marrow cells using deep learning-based Morphogo system.
Sci Rep. 2023 Aug 17;13(1):13364. doi: 10.1038/s41598-023-40424-x.
2
Therapeutic Plateletpheresis in Patients With Thrombocytosis: Gender, Hemoglobin Before Apheresis Significantly Affect Collection Efficiency.
Front Med (Lausanne). 2021 Dec 24;8:762419. doi: 10.3389/fmed.2021.762419. eCollection 2021.
3
[WHO classification of myeloid neoplasms].
Pathologe. 2018 Dec;39(Suppl 2):315-318. doi: 10.1007/s00292-018-0534-7.
4
Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide.
Blood. 2017 Oct 26;130(17):1889-1897. doi: 10.1182/blood-2017-05-785790. Epub 2017 Aug 9.
Zotero 插件